Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-16

FDA Approved: JUNEL FE 24 — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for JUNEL FE 24, a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol with ferrous f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JUNEL FE 24 (NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE)

Snippet

SUPPL AP for JUNEL FE 24 (NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE)